Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 23 | 2026Lilly Launches Zepbound KwikPen; Allurion Gains FDA Approval; Eversense 365 Launches with twiist AID System; February CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 23 | 2026Cagrisema Gets RedefinedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 20 | 2026Tandem Q4 ’25 Earnings; Verdiva Obesity Pipeline Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 19 | 2026Zealand and Madrigal Q4 ’25 Earnings; Novo Initiates Ph2 T2DM Study of Internal Triple-Agonist; Goodpath Expands Wegovy AccessPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics Feb 18 | 2026Beta Bionics and Insulet Q4 ’25 Earnings; Lilly Taltz+Zepbound PsO Combination Data; Zealand Ph1a Kv1.3 Inhibitor Topline ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 17 | 2026Lilly Retatrutide Risk Mitigation; Medtronic CY Q4 ’25 Earnings; 7.2mg Wegovy EU Approval; Lilly Targets India for Manufacturing Hub; EC Approval of Myqorzo; Esperion and Alkem Reach Generic BA AgreementPurchase Blast
$599
Posted in: Autologous, Basal Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Topics Feb 14 | 2026Dexcom, Vertex, and Biocon Q4 ’25 Earnings; Lilly Stockpiles Orforglipron Ahead of Launch Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 12 | 2026Viking’s Oral VK2735 Progresses to Ph3; Novo to Sell Wegovy Vials; Alnylam Q4 ’25 Earnings; Sanofi Appoints New CEOPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 11 | 2026Madrigal Partners for siRNA MASH Program; Novo Initiates Ph2 Obesity Study for Triple Agonist; Eccogene Reports Topline Ph1b Elecoglipron Data; Ascletis Selects Another Obesity Candidate; Cascade Raises $72M; Hoth Shares Pre-Clinical Obesity/MASH DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 10 | 2026AZ’s Oral GLP-1RA Progresses to Ph3; Kailera and Hengrui Ph2 Oral Ribupatide Data; Pfizer Registers VESPER-5; Ph3 Zenagamtide vs Semaglutide H2H Study; Sava Preliminary CGM Data Purchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other, Topics Feb 10 | 2026Thoughts on The TrumpRx Launch: The Future Booking.com of Obesity Drugs?Purchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other, Topics Feb 09 | 2026Novo and Hims Compounding Saga Concludes?; Obesity Spotlighted in the Super Bowl; Lilly Registers ENLIGHTEN-6 Eloralintide Study; MannKind Initiates Afrezza New Onset T1DM TrialPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Feb 06 | 2026Novo Super Bowl Ad; FDA Takes Stance on Compounding; Arrowhead Q4 ’25 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Feb 05 | 2026Hims Launches Compounded Sema Pill; Novo London, AbbVie, GSK, and Novartis Q4 ’25 Earnings; Stelo Smart Meal Logging Updates; Abbott FDA Warning Letter and Class I Recall; Rare Pediatric PRV Program Reauthorized; Sciwind Ph3 OSA StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 04 | 2026Novo Headwinds to Persist in 2026; Q4 ’25 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 04 | 2026Lilly Q4 ‘25 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Feb 03 | 2026Pfizer, Merck, and Amgen Q4 ’25 Earnings; VESPER-3 Topline Results; Novo Business Updates; PepLib and Lilly Peptide PartnershipPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i, Topics Feb 02 | 2026Novo Reports Topline Cagrisema T2DM Data; Additional Nimacimab Results; Medtronic Expands 780G Access; SanegeneBio Partners with Roche; NMPA Approves Sciwind’s Ecnoglutide in T2DM Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 30 | 2026AZ Looks to China for Latest Obesity Deal; January CHMP Meeting Highlights; Regeneron Q4 ’25 Earnings; Lilly Builds New Site in Pennsylvania; Novo Teases Super Bowl CommercialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jan 29 | 2026Roche and Sanofi Q4 ’25 earnings; New Fractyl Revita DataPurchase Blast